UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 163

Sortiert nach

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-10, Vol.373 (17), p.1627-1639

2015

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Volltextzugriff (PDF)

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

Annals of oncology, 2023-02, Vol.34 (2), p.173-185

2023

Volltextzugriff (PDF)

PC05.04 ICIs for Elderly Patients with Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S147-S147

Borghaei, H.

2019

Volltextzugriff (PDF)

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma

Annals of oncology, 2016-09, Vol.27 (9), p.1782-1787

2016

Volltextzugriff (PDF)

PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S61-S61

2021

Volltextzugriff (PDF)

Comparative Effectiveness of Standard Versus High-Dose Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S200-S201

2016

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Annals of oncology, 2019-10, Vol.30, p.v917-v918

2019

Volltextzugriff (PDF)

Patterns and Predictors of Failure Following Definitive Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E477-E478

2016

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031

2019

Volltextzugriff (PDF)

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.1039-1046

2014

Volltextzugriff (PDF)

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S32-S33

2014

Volltextzugriff (PDF)

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S34-S35

2014

Volltextzugriff (PDF)

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

ESMO open, 2023-12, Vol.8 (6), p.102065-102065, Article 102065

2023

Volltextzugriff (PDF)

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Volltextzugriff (PDF)

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

European journal of cancer (1990), 2015-09, Vol.51, p.S632-S632

2015

Volltextzugriff (PDF)

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

European journal of cancer (1990), 2015-09, Vol.51, p.S632-S633

2015

Volltextzugriff (PDF)

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

European journal of cancer (1990), 2015-09, Vol.51, p.S599-S599

2015

Volltextzugriff (PDF)

Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S563-S563

2012

Volltextzugriff (PDF)

Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor–Targeted SN-38 Conjugate, in Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S64-S65

2014

Volltextzugriff (PDF)

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S31-S31

2014

Volltextzugriff (PDF)

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S2-S2

2014

Volltextzugriff (PDF)

Effectiveness and Timing of Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Carcinoma (LS-SCLC) Patients: A Single Institution Experience

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S518-S518

2013

Volltextzugriff (PDF)

Twice Daily Versus Once Daily Radiation Therapy in Unselected Limited-Stage Small Cell Lung Cancer Patients: “Medicine-Based” Evidence

International journal of radiation oncology, biology, physics, 2013-10, Vol.87 (2), p.S507-S508

2013

Volltextzugriff (PDF)

EP11.03-35 Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S635-S636

2023

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(154)

Publikationsform

Artikel
(163)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(25)
Oncology
(22)
Hematology, Oncology And Palliative Medicine
(18)
Female
(13)
Radiology
(13)
Aged
(11)
Middle Aged
(11)
Chemotherapy
(10)
Adult
(9)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Immunotherapy
(9)
Lung Cancer
(9)
Lung Neoplasms - Drug Therapy
(9)
Male
(9)
Mutation
(8)
Aged, 80 And Over
(6)
B7-H1 Antigen - Metabolism
(6)
Cancer Therapies
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

PC05.04 ICIs for Elderly Patients with Advanced NSCLC

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma

PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis

Comparative Effectiveness of Standard Versus High-Dose Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

Patterns and Predictors of Failure Following Definitive Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs)

Role of Radiation Therapy for Malignant Thymoma: A Single Institution Experience

Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitor–Targeted SN-38 Conjugate, in Small Cell Lung Cancer

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Effectiveness and Timing of Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Carcinoma (LS-SCLC) Patients: A Single Institution Experience

Twice Daily Versus Once Daily Radiation Therapy in Unselected Limited-Stage Small Cell Lung Cancer Patients: “Medicine-Based” Evidence

EP11.03-35 Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy

Suchergebnisse filtern